Janney Montgomery Scott LLC Reduces Stock Position in Privia Health Group, Inc. $PRVA

Janney Montgomery Scott LLC lessened its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 5.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,418 shares of the company’s stock after selling 2,953 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Privia Health Group were worth $1,206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRVA. GAMMA Investing LLC increased its position in Privia Health Group by 4,683.8% during the 1st quarter. GAMMA Investing LLC now owns 64,342 shares of the company’s stock worth $1,444,000 after purchasing an additional 62,997 shares in the last quarter. Park Avenue Securities LLC boosted its stake in Privia Health Group by 3.6% in the 1st quarter. Park Avenue Securities LLC now owns 15,229 shares of the company’s stock worth $342,000 after buying an additional 532 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Privia Health Group by 9.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 261,918 shares of the company’s stock worth $5,880,000 after buying an additional 21,590 shares during the last quarter. Bessemer Group Inc. boosted its stake in Privia Health Group by 2,393.4% in the 1st quarter. Bessemer Group Inc. now owns 2,269 shares of the company’s stock worth $51,000 after buying an additional 2,178 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its stake in Privia Health Group by 2.9% in the 1st quarter. Peregrine Capital Management LLC now owns 330,130 shares of the company’s stock worth $7,411,000 after buying an additional 9,362 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on PRVA shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Privia Health Group in a research note on Wednesday, October 8th. Piper Sandler decreased their price target on Privia Health Group from $36.00 to $35.00 and set an “overweight” rating on the stock in a research note on Monday, August 11th. Zacks Research raised Privia Health Group from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. Stephens reissued an “overweight” rating and issued a $32.00 price target on shares of Privia Health Group in a research note on Wednesday, September 24th. Finally, JMP Securities raised their price target on Privia Health Group from $29.00 to $30.00 and gave the stock a “market outperform” rating in a research note on Friday, August 29th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Privia Health Group currently has an average rating of “Moderate Buy” and a consensus target price of $28.91.

Privia Health Group Price Performance

NASDAQ PRVA opened at $24.08 on Monday. The firm has a market capitalization of $2.96 billion, a P/E ratio of 218.93, a P/E/G ratio of 3.28 and a beta of 0.83. Privia Health Group, Inc. has a 1-year low of $17.03 and a 1-year high of $26.09. The business’s 50-day simple moving average is $22.46 and its 200-day simple moving average is $22.45.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Tuesday, June 7th. The company reported $0.10 earnings per share for the quarter. The business had revenue of $213.61 million for the quarter. Privia Health Group had a return on equity of 2.13% and a net margin of 0.78%. On average, equities research analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.